Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic … – Citizen Tribune,

… Drug Candidate CB03 in First-in-Human Phase I Clinical Trial … CB03 is a candidate drug for the treatment of refractory epilepsy, …, … Drug Candidate CB03 in First-in-Human Phase I Clinical Trial … CB03 is a candidate drug for the treatment of refractory epilepsy, …, Read More

Scroll to Top